Navigation Links
Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
Date:4/20/2011

CAMBRIDGE, Mass., April 20, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

MM-111 is a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between ErbB2/HER2 and ErbB3/HER3 thus disabling downstream signaling, including the phosphatidylinositol 3-kinase (PI3K) pathway, and preventing tumor proliferation. In this study, Merrimack is evaluating whether MM-111 could be safely added to standard therapies used to treat HER2 positive cancers. The study could also provide preliminary evidence of activity in patients with advanced/metastatic HER2 positive disease, an area of high unmet medical need for which there are limited treatment options.

"HER2 positive cancers are historically more aggressive and carry a poorer prognosis than other types of solid tumors," says Clet Niyikiza, Ph.D., Executive Vice President of Development, Merrimack Pharmaceuticals. "Patients with HER2 positive metastatic cancer eventually progress or are intolerant of current approved regimens. Close to half of the patients treated with such regimens fail to respond."

The Phase 1 study will evaluate the human safety and pharmacokinetics of MM-111 when administered in combination with either 1) cisplatin, capecitabine, and trastuzumab; 2) lapatinib and trastuzumab; or 3) paclitaxel and trastuzumab in patients with HER2 positive solid tumors. The study is being run in collaboration with US Oncology, a leading integrated oncology company that is affiliated with more than 1,400 physicians nationwide.

"Because ErbB3 activation has been indicated as a cause of resistance to current HER2 targeted treatments and chemotherapies, we pl
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
2. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
3. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
4. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
5. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
7. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
10. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
11. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Hill-Rom Holdings, Inc. ... to a management presentation at the Morgan Stanley Global ... EDT. You are invited to listen to ... http://ir.hill-rom.com/events.cfm or access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP ... available one hour after conclusion of the live event ...
(Date:8/27/2014)... An experimental drug designed to help regulate the blood,s iron ... of inflammation, according to results from the first human ... Blood , the Journal of the American ... a condition that occurs when red blood cells are in ... has anemia, the body does not get enough oxygen, since ...
(Date:8/27/2014)... , Aug. 27, 2014 ... research report is available in its ... for Application and Approval of Imported ... Practices (2014 Edition) ... Now, Chinese regulations on medical ...
Breaking Medicine Technology:Drug Represents First Potential Treatment for Common Anemia 2Drug Represents First Potential Treatment for Common Anemia 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10
(Date:8/27/2014)... While many scientists are trying to prevent the ... autophagy, researchers at Virginia Commonwealth University Massey Cancer ... that causes the process to culminate in cell ... targets the p62 protein, which is often referred ... role in disposing unwanted cellular proteins during autophagy. ...
(Date:8/27/2014)... August 27, 2014 Representatives with ... Italy to its list of destinations for International Yoga ... Recharge Retreats, explained that the company chose Italy due ... for yoga teacher trainings since it's an easy flight ... for people traveling from all over Europe, UK, Africa, ...
(Date:8/27/2014)... Lighthouse Payment Services Inc ., a ... will exhibit its image-based lockbox services at the Independent ... in beautiful Lake Placid, New York from September ... held at the Lake Placid Convention Center and will ... in addition to a variety of vendors exhibiting the ...
(Date:8/27/2014)... Sugar Manufacturing in Australia ... in global supply and demand, which have contributed to ... industry derives a large share of its revenue from ... dynamics, with supply and prices being determined by larger ... Australian dollar for the majority of the past five ...
(Date:8/27/2014)... SCOTT Sports is excited to ... indoor mountain bike and BMX park. SCOTT will provide ... both adult and youth sizes for the park’s rental bike ... warehouse in Ogden, Utah, recently moved its U.S. headquarters from ... proud to be a partner with the Wasatch Bike Park, ...
Breaking Medicine News(10 mins):Health News:Promising new cancer therapy uses molecular 'Trash Man' to exploit a common cancer defense 2Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 2Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2
... MORGANTOWN, W.Va., April 17 Even though suicide outranks ... States, incomplete death certificates thwart healthcare policymakers who want ... Hispanic populations, a WVU study shows."The Institute ... commit suicide have been diagnosed with a mental disorder, ...
... LAUDERDALE, Fla., April 17 Former partner and accomplished ... & Scherer LLP as a partner.Genovese, most recently of ... has tried over 150 jury trials and has had ... Times and the Wall Street Journal. He is well ...
... 17 Recent economic events have led people to ... families. Many are feeling that it is time to ... and they are deciding to start their families now, ... cocooning is reflected in a growing number of couples ...
... 17 Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: ... its subsidiary, Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), ... for the purchase of all outstanding Ordinary Shares of ... now expire at 5:00 p.m., New York City time, ...
... April 30, 2009 - 9:00 a.m. ET HOPKINTON, Mass., ... CALP ) will conduct a conference call discussing ... a.m. ET on Thursday, April 30. Kevin Hrusovsky, ... Financial Officer, will host the call. Management will discuss ...
... 19 - April 25 HARRISBURG, Pa., April 17 ... for selflessly giving their time to help communities prepare ... to join those important efforts. "National Volunteer Week starts ... volunteers for generously sharing their time, energy and expertise ...
Cached Medicine News:Health News:Team Uncovers Discrepancy in Death Certificates Listing Suicide 2Health News:Veteran Medical Malpractice Litigator Gary S. Genovese Re-Joins Conrad & Scherer LLP 2Health News:Family Cocooning in the Face of Recession Leads to Expanded Business for Bay Area Fertility Doctor - Dr. Danielle Lane 2Health News:Sun Pharmaceutical Extends Tender Offer for Taro 2Health News:Sun Pharmaceutical Extends Tender Offer for Taro 3Health News:Caliper Life Sciences' First Quarter 2009 Financial Results Conference Call Notice 2Health News:PA Secretary of Health Recognizes Pennsylvania Volunteers; Urges Greater Citizen Involvement 2
Inoculum Broth...
... Molecular Biology Buffers are ready-to-use solutions ideal ... applications. Each reagent is prepared with 18 ... filter, and filled into sterile bottles., ... control standards to ensure lot-to-lot consistency. ...
1.2% Tryptone, 2.4% Yeast Extract, 0.4% Glycerol, with 100ml of 10x Phosphate buffer supplement (0190-01)....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride....
Medicine Products: